By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Arcion Therapeutics 

2400 Boston Street
Suite 330
Baltimore  Maryland  21224  U.S.A.
Phone: 410-522-8701 Fax: n/a




Company News
Arcion Therapeutics Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain 1/4/2012 11:14:22 AM
Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 6/14/2011 9:07:06 AM
Arcion Therapeutics Receives FDA Fast Track Designation for ARC-4558 for the Treatment of Pain Associated with Painful Diabetic Neuropathy 9/14/2010 7:53:40 AM
Arcion Therapeutics' Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN) 7/20/2010 9:29:39 AM
Anesiva, Inc. (ANSV) Stockholders Approved Merger With Arcion Therapeutics; Merger Remains Contingent on Other Closing Conditions 12/8/2009 6:56:29 AM
Anesiva, Inc. (ANSV) and Arcion Therapeutics Announce Merger Agreement; Creates New Company Focused on Targeted Pain Therapeutics 8/5/2009 6:12:59 AM
Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy 5/7/2009 11:12:15 AM
Arcion Therapeutics Raises $8.8 Million ''A'' Round 1/9/2008 7:39:57 AM